Metabolic Effects of Acute Thiamine Depletion Are Reversed by Rapamycin in Breast and Leukemia Cells

Thiamine-dependent enzymes (TDEs) control metabolic pathways that are frequently altered in cancer and therefore present cancer-relevant targets. We have previously shown that the recombinant enzyme thiaminase cleaves and depletes intracellular thiamine, has growth inhibitory activity against leukemia and breast cancer cell lines, and that its growth inhibitory effects were reversed in leukemia cell lines by rapamycin. Now, we first show further evidence of thiaminase therapeutic potential by demonstrating its activity against breast and leukemia xenografts, and against a primary leukemia xenograft. We therefore further explored the metabolic effects of thiaminase in combination with rapamycin in leukemia and breast cell lines. Thiaminase decreased oxygen consumption rate and increased extracellular acidification rate, consistent with the inhibitory effect of acute thiamine depletion on the activity of the TDEs pyruvate dehydrogenase and 2-oxoglutarate dehydrogenase complexes; these effects were reversed by rapamycin. Metabolomic studies demonstrated intracellular thiamine depletion and the presence of the thiazole cleavage product in thiaminase-treated cells, providing validation of the experimental procedures. Accumulation of ribose and ribulose in both cell lines support the thiaminase-mediated suppression of the TDE transketolase. Interestingly, thiaminase suppression of another TDE, branched chain amino ketoacid dehydrogenase (BCKDH), showed very different patterns in the two cell lines: in RS4 leukemia cells it led to an increase in BCKDH substrates, and in MCF-7 breast cancer cells it led to a decrease in BCKDH products. Immunoblot analyses showed corresponding differences in expression of BCKDH pathway enzymes, and partial protection of thiaminase growth inhibition by gabapentin indicated that BCKDH inhibition may be a mechanism of thiaminase-mediated toxicity. Surprisingly, most of thiaminase-mediated metabolomic effects were also reversed by rapamycin. Thus, these studies demonstrate that acute intracellular thiamine depletion by recombinant thiaminase results in metabolic changes in thiamine-dependent metabolism, and demonstrate a previously unrecognized role of mTOR signaling in the regulation of thiamine-dependent metabolism.

[1]  Jason Zastre,et al.  Linking vitamin B1 with cancer cell metabolism , 2013, Cancer & metabolism.

[2]  M. Pollak,et al.  Why Cancer & Metabolism? Why now? , 2013, Cancer & metabolism.

[3]  J. Moscow,et al.  Low-thiamine diet increases mammary tumor latency in FVB/N-Tg(MMTVneu) mice. , 2012, International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition.

[4]  D. S. St. Clair,et al.  Pharmacologic Properties of Polyethylene Glycol-Modified Bacillus thiaminolyticus Thiaminase I Enzyme , 2012, Journal of Pharmacology and Experimental Therapeutics.

[5]  Y. Bae,et al.  Linear Chain PEGylated Recombinant Bacillus Thiaminolyticus Thiaminase I Enzyme Has Growth Inhibitory Activity against Lymphoid Leukemia Cell Lines , 2011, Molecular Cancer Therapeutics.

[6]  Liping Wei,et al.  Chemical genomic screening reveals synergism between parthenolide and inhibitors of the PI-3 kinase and mTOR pathways. , 2010, Blood.

[7]  Anne M. Evans,et al.  Organization of GC/MS and LC/MS metabolomics data into chemical libraries , 2010, J. Cheminformatics.

[8]  Hui-ying Yu,et al.  Sensitivity of breast cancer cell lines to recombinant thiaminase I , 2010, Cancer Chemotherapy and Pharmacology.

[9]  Corey D. DeHaven,et al.  Integrated, nontargeted ultrahigh performance liquid chromatography/electrospray ionization tandem mass spectrometry platform for the identification and relative quantification of the small-molecule complement of biological systems. , 2009, Analytical chemistry.

[10]  Lining Guo,et al.  Untargeted Metabolomic Profiling as an Evaluative Tool of Fenofibrate-Induced Toxicology in Fischer 344 Male Rats , 2009, Toxicologic pathology.

[11]  S. Santra,et al.  Experience of nitisinone for the pharmacological treatment of hereditary tyrosinaemia type 1 , 2008, Expert opinion on pharmacotherapy.

[12]  S. Weiler,et al.  Synthesis, in vitro and in vivo activity of thiamine antagonist transketolase inhibitors. , 2008, Bioorganic & medicinal chemistry letters.

[13]  S. Weiler,et al.  Prodrug thiamine analogs as inhibitors of the enzyme transketolase. , 2008, Bioorganic & medicinal chemistry letters.

[14]  P. Veldhoven,et al.  The role of 2-hydroxyacyl-CoA lyase, a thiamin pyrophosphate-dependent enzyme, in the peroxisomal metabolism of 3-methyl-branched fatty acids and 2-hydroxy straight-chain fatty acids. , 2007, Biochemical Society transactions.

[15]  A. Stromberg,et al.  Thiamine transporter gene expression and exogenous thiamine modulate the expression of genes involved in drug and prostaglandin metabolism in breast cancer cells. , 2004, Molecular cancer research : MCR.

[16]  Xin Lu,et al.  Down-regulation of thiamine transporter THTR2 gene expression in breast cancer and its association with resistance to apoptosis. , 2003, Molecular cancer research : MCR.

[17]  M. Aschner,et al.  Role of Branched‐Chain Aminotransferase Isoenzymes and Gabapentin in Neurotransmitter Metabolism , 1998, Journal of neurochemistry.

[18]  P. Veldhoven,et al.  The role of 2-hydroxyacyl-CoA lyase 1, a thiamine pyrophosphate dependent peroxisomal enzyme, in the metabolism of 3-methyl-branched fatty acids and 2-hydroxy straight chain fatty acids , 2007 .

[19]  F. McLafferty,et al.  Mechanistic Studies on Thiaminase I OVEREXPRESSION AND IDENTIFICATION OF THE ACTIVE SITE NUCLEOPHILE* , 1996 .